3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
4
Endocrine
4
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Colorectal Neoplasms
20
Pancreatic Neoplasms
11
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Rectal Neoplasms
5
Colonic Neoplasms
5
Thyroid Neoplasms
4
Multiple Myeloma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Hematologic Neoplasms
3
Glioma
3
Breast Neoplasms
3
Bile Duct Neoplasms
3
Triple Negative Breast Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Carcinoma, Hepatocellular
2
Adenocarcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Stomach Neoplasms
1
Interventions
selpercatinib
3
Trastuzumab
2
Radiotherapy
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trametinib
1
tovorafenib
1
tipifarnib
1
sargramostim
1
pralsetinib
1
mercaptoundecahydrododecaborate
1
entrectinib
1
dabrafenib
1
cobimetinib
1
alectinib
1
aldesleukin
1
Vemurafenib
1
Taxes
1
Tamoxifen
1
Ritonavir
1
Paclitaxel
1
Nivolumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Indinavir
1
Famotidine
1
Doxorubicin
1
Cisplatin
1
Bortezomib
1
4-boronophenylalanine-fructose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Cancer, Papillary
×
trametinib
×
Gastrointestinal
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled